<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02730884</url>
  </required_header>
  <id_info>
    <org_study_id>2014-0546</org_study_id>
    <secondary_id>NCI-2016-00761</secondary_id>
    <nct_id>NCT02730884</nct_id>
  </id_info>
  <brief_title>Single-Arm Study of the Efficacy and Safety of Oral Rigosertib in Patients With Myelofibrosis (MF) and Anemia</brief_title>
  <official_title>A Phase II Single-Arm Study of the Efficacy and Safety of Oral Rigosertib in Patients With Myelofibrosis (MF) and Anemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Onconova Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to learn if rigosertib can help to control MF in&#xD;
      patients with anemia. The safety of this drug will also be studied.&#xD;
&#xD;
      This is an investigational study. Rigosertib is not FDA-approved or commercially available.&#xD;
      It is currently being used for research purposes only. The study doctor can explain how the&#xD;
      study drug is designed to work.&#xD;
&#xD;
      Up to 35 participants will be enrolled in this study. All will be enrolled at MD Anderson.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Drug Administration:&#xD;
&#xD;
      If participant is found to be eligible to take part in this study, participant will take&#xD;
      rigosertib capsules by mouth 2 times each day (1 morning dose, 1 afternoon dose) for 48&#xD;
      weeks. Participant will take participant's morning dose on an empty stomach. Participant's&#xD;
      afternoon dose should be taken at about 3:00 pm (±1 hour), at least 2 hours after lunch.&#xD;
      Participant should drink at least a ½ gallon of water each day. Rigosertib should be&#xD;
      refrigerated.&#xD;
&#xD;
      Participant will also be given a study drug diary. Participant should write down each dose of&#xD;
      study drug that participant takes, when participant takes it, and if participant misses or&#xD;
      vomit any doses. If participant misses or vomits a dose of rigosertib, participant should not&#xD;
      make up the dose. Participant should take the next scheduled dose as planned. Every 4 weeks&#xD;
      for 12 weeks, then every 8 weeks thereafter, participant should bring any leftover rigosertib&#xD;
      capsules and participant's study drug diary with participant to the clinic.&#xD;
&#xD;
      Study Visits:&#xD;
&#xD;
      On Cycle 1 Day 1:&#xD;
&#xD;
        -  Participant will have a physical exam.&#xD;
&#xD;
        -  Blood (about 2-3 teaspoons) and urine will be collected for routine tests.&#xD;
&#xD;
        -  Blood (about 2 teaspoons) will be drawn for pharmacokinetic (PK) testing about 1 hour&#xD;
           after participant's dose of study drug. PK testing measures the amount of study drug in&#xD;
           the body at different time points.&#xD;
&#xD;
        -  Participant will complete a questionnaire about participant's quality of life. It should&#xD;
           take about 10-15 minutes.&#xD;
&#xD;
        -  If the doctor thinks it is needed, participant will have a computed tomography (CT) or&#xD;
           magnetic resonance imaging (MRI) scan to check the status of the disease.&#xD;
&#xD;
      Each week, blood (about 2-3 teaspoons) will be drawn for routine tests. If the study doctor&#xD;
      approves it, participant may have these weekly blood draws at a local lab closer to&#xD;
      participant's home. The results from these routine tests will be sent to the study doctor.&#xD;
&#xD;
      On Day 1 of Week 4, blood (about 2 teaspoons each time) will be drawn for PK testing before&#xD;
      and 1 hour after participant's dose of study drug.&#xD;
&#xD;
      At Weeks 24 and 48 (± 1 week):&#xD;
&#xD;
        -  Participant will have a bone marrow aspirate/biopsy performed to check the status of the&#xD;
           disease. This sample may also be used for cytogenetic testing.&#xD;
&#xD;
        -  If participant had a CT/MRI scan performed during Week 1, participant will have another&#xD;
           CT/MRI scan to check the status of the disease.&#xD;
&#xD;
        -  If participant can become pregnant, urine will be collected for a pregnancy test.&#xD;
&#xD;
      Every 4 weeks until Week 12 and then every 8 weeks after that:&#xD;
&#xD;
        -  Participant will have a physical exam.&#xD;
&#xD;
        -  Blood (about 2-3 teaspoons) and urine will be collected for routine tests.&#xD;
&#xD;
        -  Participant will complete a questionnaire about participant's quality of life.&#xD;
&#xD;
      Length of Study:&#xD;
&#xD;
      Participant may continue taking the study drug for up to 48 weeks. Participant will no longer&#xD;
      be able to take the study drugs if the disease gets worse, if intolerable side effects occur,&#xD;
      or if participant is unable to follow study directions.&#xD;
&#xD;
      If the doctor thinks it is in participant's best interest, participant may be able to&#xD;
      continue taking the study drug after 48 weeks. The study doctor will discuss this with&#xD;
      participant.&#xD;
&#xD;
      Participation on the study will be over after the end-of-study visit.&#xD;
&#xD;
      End-of-Study Visit:&#xD;
&#xD;
      About 4 weeks after participant's last dose of study drug, participant will have an&#xD;
      end-of-study visit. At this visit:&#xD;
&#xD;
        -  Participant will have a physical exam.&#xD;
&#xD;
        -  Blood (about 2-3 teaspoons) and urine will be collected for routine tests. This routine&#xD;
           blood and urine collection will also include a pregnancy test if participant can become&#xD;
           pregnant.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Terminated Per PIs request due to low accrual&#xD;
  </why_stopped>
  <start_date type="Actual">August 16, 2017</start_date>
  <completion_date type="Actual">August 22, 2019</completion_date>
  <primary_completion_date type="Actual">August 22, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Spleen Volume Response</measure>
    <time_frame>Baseline and 48 weeks</time_frame>
    <description>Spleen response defined as ≥ 35% spleen volume reduction from Baseline, which must be confirmed by MRI or CT measurement per revised International Working Group for Myelofibrosis Research and Treatment (IWG MRT) response criteria.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Participants With Anemia Response</measure>
    <time_frame>Baseline and 48 weeks</time_frame>
    <description>Anemia response defined as the proportion of transfusion-independent patients with Hgb increase of at least 2 g/dL from Baseline or the proportion of transfusion-dependent patients becoming transfusion independent for at least 12 weeks as defined in 2013 International Working Group for Myelofibrosis Research and Treatment (IWG-MRT) criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Symptoms Response</measure>
    <time_frame>48 weeks</time_frame>
    <description>Symptoms response defined as the proportion of patients achieving ≥ 50% reduction in the Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPN-SAF TSS) at any time before Week 48.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Leukemia</condition>
  <condition>Myelofibrosis</condition>
  <condition>Anemia</condition>
  <condition>Splenomegaly</condition>
  <arm_group>
    <arm_group_label>Rigosertib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive oral Rigosertib under fasting conditions twice a day on a continuous basis. Quality of life questionnaire completed on Day 1 of Cycle 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rigosertib</intervention_name>
    <description>Participants take 560 mg Rigosertib by mouth in the morning (two 280 mg capsules) and 560 mg Rigosertib in the afternoon.</description>
    <arm_group_label>Rigosertib</arm_group_label>
    <other_name>ON 01910.Na</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Questionnaire</intervention_name>
    <description>Quality of life questionnaire completed on Day 1 of Cycle 1. It should take about 10-15 minutes to complete.</description>
    <arm_group_label>Rigosertib</arm_group_label>
    <other_name>Survey</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. &gt;/= 18 years of age;&#xD;
&#xD;
          2. Diagnosis of primary myelofibrosis (PMF) or post-polycythemia vera (post-PV) MF or&#xD;
             post-essential thrombocythemia (post-ET) MF based on the World Health Organization&#xD;
             (WHO) criteria or the International Working Group-Myeloproliferative Neoplasms&#xD;
             Research and Treatment (IWG-MRT) criteria, which must be confirmed by BM aspirate&#xD;
             and/or biopsy within 6 weeks prior to Screening. Measurement of JAK2 V617F allele&#xD;
             burden in Bone Marrow (BM) samples, if not done within 6 months prior to Screening,&#xD;
             must be provided with the Screening BM biopsy/aspirate report (patients are eligible&#xD;
             regardless of JAK2 mutation status);&#xD;
&#xD;
          3. Anemia or RBC-transfusion dependence defined as follows: a) Anemia: defined for the&#xD;
             purpose of this protocol as 1) a hemoglobin level &lt;10 g/L on every determination over&#xD;
             84 days before study-entry, without red blood cell (RBC)-transfusions, or 2) a&#xD;
             hemoglobin level &lt;10 g/L on a patient that is receiving RBC-transfusions periodically&#xD;
             but not meeting criteria for transfusion-dependent patient as defined below. The&#xD;
             baseline hemoglobin value for these subjects is the lowest hemoglobin level during the&#xD;
             antecedent 84 days; b) RBC-transfusion-dependence: RBC-transfusion-frequency of &gt;/=2&#xD;
             units packed red blood cells (PRBC)/28 days averaged over 84 days immediately&#xD;
             pre-study-entry. There must not be any consecutive 42 days without an RBC-transfusion&#xD;
             during this interval.&#xD;
&#xD;
          4. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2;&#xD;
&#xD;
          5. Willing to adhere to the prohibitions and restrictions specified in this protocol&#xD;
             (Notation: the subject's willingness to adhere to prohibitions and restrictions must&#xD;
             be clearly communicated in the on-study note);&#xD;
&#xD;
          6. The patient must signed an informed consent form (ICF) indicating that s/he&#xD;
             understands the purpose of, and procedures required for, the study and is willing to&#xD;
             participate.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Ongoing clinically significant anemia due to factors such as known iron, vitamin B12,&#xD;
             or folate deficiencies, auto-immune or hereditary hemolysis, or gastrointestinal (GI)&#xD;
             bleeding;&#xD;
&#xD;
          2. Serum ferritin &lt; 50 ng/mL;&#xD;
&#xD;
          3. Any active malignancy within the past year, except basal cell or squamous cell skin&#xD;
             cancer or carcinoma in situ of the cervix or breast; patients with history of prior&#xD;
             malignancies should be free of disease for at least 3 years to be eligible for this&#xD;
             study.&#xD;
&#xD;
          4. Uncontrolled intercurrent illness, including, but not limited to symptomatic&#xD;
             congestive heart failure, unstable angina pectoris, or cardiac arrhythmia;&#xD;
&#xD;
          5. Active infection not adequately responding to appropriate therapy;&#xD;
&#xD;
          6. Direct bilirubin &gt;/= 2.0 mg/dL not related to hemolysis or Gilbert's disease;&#xD;
&#xD;
          7. Alanine transaminase (ALT) or aspartate transaminase (AST)&gt;/= 2.5 x the upper limit of&#xD;
             normal (ULN);&#xD;
&#xD;
          8. Serum creatinine &gt;/= 2.5 mg/dL;&#xD;
&#xD;
          9. Ascites requiring active medical management including paracentesis;&#xD;
&#xD;
         10. Hyponatremia (defined as serum sodium level &lt; 130 mEq/L);&#xD;
&#xD;
         11. Female patients who are pregnant or lactating;&#xD;
&#xD;
         12. Patients of childbearing potential (ie, women of childbearing potential and men with&#xD;
             female partners of childbearing potential) who are unwilling to follow strict&#xD;
             contraception requirements (including 2 reliable methods in combination: 1&#xD;
             non-hormonal, highly-reliable method [diaphragm, condoms with spermicidal foam or&#xD;
             jelly, or sterilization] plus 1 additional reliable method [birth control pills,&#xD;
             intrauterine device, contraceptive injections, or contraceptive patches]) before entry&#xD;
             and throughout the study, up to and including the 30-day non-treatment follow-up&#xD;
             period;&#xD;
&#xD;
         13. Female patients of childbearing potential who have a positive blood or urine pregnancy&#xD;
             test at Screening;&#xD;
&#xD;
         14. Major surgery without full recovery or major surgery within 3 weeks of Screening;&#xD;
&#xD;
         15. Uncontrolled hypertension (defined as a sustained systolic pressure &gt;/= 160 mmHg&#xD;
             and/or a diastolic pressure &gt;/= 110 mmHg);&#xD;
&#xD;
         16. New onset seizures (within 3 months prior to Screening) or poorly controlled seizures;&#xD;
&#xD;
         17. Any other concurrent investigational agent or chemotherapy, radiotherapy, or&#xD;
             immunotherapy;&#xD;
&#xD;
         18. Chronic use (&gt; 2 weeks) of corticosteroids (prednisone &gt;/= 10 mg/24 hr equivalent)&#xD;
             within 4 weeks of Screening;&#xD;
&#xD;
         19. Investigational therapy within 2 weeks of Screening;&#xD;
&#xD;
         20. Psychiatric illness or social situation that would limit the patient's ability to&#xD;
             tolerate and/or comply with study requirements.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jorge Cortes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>March 24, 2016</study_first_submitted>
  <study_first_submitted_qc>April 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 7, 2016</study_first_posted>
  <results_first_submitted>July 22, 2020</results_first_submitted>
  <results_first_submitted_qc>August 5, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 7, 2020</results_first_posted>
  <last_update_submitted>August 5, 2020</last_update_submitted>
  <last_update_submitted_qc>August 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Leukemia</keyword>
  <keyword>Myelofibrosis</keyword>
  <keyword>MF</keyword>
  <keyword>Anemia</keyword>
  <keyword>Splenomegaly</keyword>
  <keyword>Post-polycythemia vera MF</keyword>
  <keyword>post-PV</keyword>
  <keyword>post-essential thrombocythemia MF</keyword>
  <keyword>post-ET</keyword>
  <keyword>Rigosertib</keyword>
  <keyword>ON 01910.Na</keyword>
  <keyword>Questionnaire</keyword>
  <keyword>Survey</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Primary Myelofibrosis</mesh_term>
    <mesh_term>Splenomegaly</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>ON 01910</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 15, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/84/NCT02730884/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment Period: August 2017 to April 2019</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Rigosertib</title>
          <description>Participants receive oral Rigosertib under fasting conditions twice a day on a continuous basis. Quality of life questionnaire completed on Day 1 of Cycle 1.&#xD;
Rigosertib: Participants take 560 mg Rigosertib by mouth in the morning (two 280 mg capsules) and 560 mg Rigosertib in the afternoon.&#xD;
Questionnaire: Quality of life questionnaire completed on Day 1 of Cycle 1. It should take about 10-15 minutes to complete.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Rigosertib</title>
          <description>Participants receive oral Rigosertib under fasting conditions twice a day on a continuous basis. Quality of life questionnaire completed on Day 1 of Cycle 1.&#xD;
Rigosertib: Participants take 560 mg Rigosertib by mouth in the morning (two 280 mg capsules) and 560 mg Rigosertib in the afternoon.&#xD;
Questionnaire: Quality of life questionnaire completed on Day 1 of Cycle 1. It should take about 10-15 minutes to complete.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67" lower_limit="59" upper_limit="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Spleen Volume Response</title>
        <description>Spleen response defined as ≥ 35% spleen volume reduction from Baseline, which must be confirmed by MRI or CT measurement per revised International Working Group for Myelofibrosis Research and Treatment (IWG MRT) response criteria.</description>
        <time_frame>Baseline and 48 weeks</time_frame>
        <population>of the three participants, one participant was not evaluable for response.</population>
        <group_list>
          <group group_id="O1">
            <title>Rigosertib</title>
            <description>Participants receive oral Rigosertib under fasting conditions twice a day on a continuous basis. Quality of life questionnaire completed on Day 1 of Cycle 1.&#xD;
Rigosertib: Participants take 560 mg Rigosertib by mouth in the morning (two 280 mg capsules) and 560 mg Rigosertib in the afternoon.&#xD;
Questionnaire: Quality of life questionnaire completed on Day 1 of Cycle 1. It should take about 10-15 minutes to complete.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Spleen Volume Response</title>
          <description>Spleen response defined as ≥ 35% spleen volume reduction from Baseline, which must be confirmed by MRI or CT measurement per revised International Working Group for Myelofibrosis Research and Treatment (IWG MRT) response criteria.</description>
          <population>of the three participants, one participant was not evaluable for response.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Participants With Anemia Response</title>
        <description>Anemia response defined as the proportion of transfusion-independent patients with Hgb increase of at least 2 g/dL from Baseline or the proportion of transfusion-dependent patients becoming transfusion independent for at least 12 weeks as defined in 2013 International Working Group for Myelofibrosis Research and Treatment (IWG-MRT) criteria.</description>
        <time_frame>Baseline and 48 weeks</time_frame>
        <population>of the three participants, one participant was not evaluable for response.</population>
        <group_list>
          <group group_id="O1">
            <title>Rigosertib</title>
            <description>Participants receive oral Rigosertib under fasting conditions twice a day on a continuous basis. Quality of life questionnaire completed on Day 1 of Cycle 1.&#xD;
Rigosertib: Participants take 560 mg Rigosertib by mouth in the morning (two 280 mg capsules) and 560 mg Rigosertib in the afternoon.&#xD;
Questionnaire: Quality of life questionnaire completed on Day 1 of Cycle 1. It should take about 10-15 minutes to complete.</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With Anemia Response</title>
          <description>Anemia response defined as the proportion of transfusion-independent patients with Hgb increase of at least 2 g/dL from Baseline or the proportion of transfusion-dependent patients becoming transfusion independent for at least 12 weeks as defined in 2013 International Working Group for Myelofibrosis Research and Treatment (IWG-MRT) criteria.</description>
          <population>of the three participants, one participant was not evaluable for response.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Symptoms Response</title>
        <description>Symptoms response defined as the proportion of patients achieving ≥ 50% reduction in the Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPN-SAF TSS) at any time before Week 48.</description>
        <time_frame>48 weeks</time_frame>
        <population>of the three participants, one participant was not evaluable for response.</population>
        <group_list>
          <group group_id="O1">
            <title>Rigosertib</title>
            <description>Participants receive oral Rigosertib under fasting conditions twice a day on a continuous basis. Quality of life questionnaire completed on Day 1 of Cycle 1.&#xD;
Rigosertib: Participants take 560 mg Rigosertib by mouth in the morning (two 280 mg capsules) and 560 mg Rigosertib in the afternoon.&#xD;
Questionnaire: Quality of life questionnaire completed on Day 1 of Cycle 1. It should take about 10-15 minutes to complete.</description>
          </group>
        </group_list>
        <measure>
          <title>Symptoms Response</title>
          <description>Symptoms response defined as the proportion of patients achieving ≥ 50% reduction in the Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPN-SAF TSS) at any time before Week 48.</description>
          <population>of the three participants, one participant was not evaluable for response.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Rigosertib</title>
          <description>Participants receive oral Rigosertib under fasting conditions twice a day on a continuous basis. Quality of life questionnaire completed on Day 1 of Cycle 1.&#xD;
Rigosertib: Participants take 560 mg Rigosertib by mouth in the morning (two 280 mg capsules) and 560 mg Rigosertib in the afternoon.&#xD;
Questionnaire: Quality of life questionnaire completed on Day 1 of Cycle 1. It should take about 10-15 minutes to complete.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Congestive Heart Failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Gastroparesis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Dirrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Would Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Neutrophil Count Decrease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary Tract Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jorge Cortes, MD/Professor</name_or_title>
      <organization>The University of Texas MD Anderson Cancer Center</organization>
      <phone>713-794-5783</phone>
      <email>jcortes@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

